Biomarkers in Samples From Younger Patients With Wilms Tumor

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01493817
First received: December 15, 2011
Last updated: December 17, 2011
Last verified: December 2011
  Purpose

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment.

PURPOSE: This research study is studying biomarkers in tissue samples from younger patients with Wilms tumor.


Condition Intervention
Kidney Cancer
Genetic: microarray analysis
Other: laboratory biomarker analysis
Other: medical chart review

Study Type: Observational
Official Title: Relationships Between Tumor-Associated Macrophages and Clinicopathological Factors in Wilms Tumor

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Relationship of tumor-associated macrophages and prognosis [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: December 2011
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To determine whether recruitment of tumor-associated macrophages is related to clinicopathological factors in Wilms tumor (tumor stage, presence of vascular invasion, tumor progression, and survival).

OUTLINE: Paraffin-embedded specimens are analyzed for macrophage markers. Results of each sample is then compared with patient's tumor stage, presence of vascular invasion, tumor progression, and survival.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Wilms tissue microarray samples provided by the Children's Oncology Group

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01493817

Sponsors and Collaborators
Children's Oncology Group
Investigators
Principal Investigator: Jessica Kandel, MD Morgan Stanley Children's Hospital of New York-Presbyterian
  More Information

Additional Information:
No publications provided

Responsible Party: Peter C. Adamson, Children's Oncology Group - Group Chair Office
ClinicalTrials.gov Identifier: NCT01493817     History of Changes
Other Study ID Numbers: CDR0000719956, COG-AREN12B1
Study First Received: December 15, 2011
Last Updated: December 17, 2011
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
Wilms tumor and other childhood kidney tumors

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Kidney Neoplasms
Wilms Tumor
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Neoplasms, Complex and Mixed
Neoplastic Syndromes, Hereditary
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on September 18, 2014